Caxton Associates (New York)’s Viking Therapeutics VKTX Stock Holding History

Caxton Associates (New York)’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-41,622	Closed	-$391K	–	645
2022 Q4	$391K	Sell	41,622 -159,411	-79%	-$712K	0.03%	289
2022 Q3	$547K	Sell	201,033 -92,615	-32%	-$303K	0.07%	220
2022 Q2	$849K	Buy	293,648 +196,977	+204%	+$487K	0.08%	154
2022 Q1	$290K	Buy	96,671 +78,165	+422%	+$280K	0.02%	368
2021 Q4	$85K	Hold	18,506	–	–	0.01%	530
2021 Q3	$116K	Sell	18,506 -13,401	-42%	-$82.8K	0.01%	422
2021 Q2	$191K	Sell	31,907 -6,843	-18%	-$40.6K	0.02%	424
2021 Q1	$245K	Buy	38,750 +18,849	+95%	+$133K	0.02%	329
2020 Q4	$112K	Buy	+19,901	New	+$121K	0.01%	130

Other funds holding VKTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Caxton Associates (New York)'s VKTX Position: Q1 2023 in Review

Caxton Associates (New York) sold out of Viking Therapeutics (VKTX) in Q1 2023, closing a stake of 41,622 shares — an estimated $391K sold.

Caxton Associates (New York) first reported a position in VKTX in Q4 2020 and held it in 9 quarters. The position peaked at $849K in Q2 2022. 184 funds tracked by Wall St. Rank hold VKTX as of Q1 2023.

Caxton Associates (New York) reported no remaining Viking Therapeutics position as of Q1 2023 after selling out during the quarter.
Caxton Associates (New York) sold 41,622 Viking Therapeutics shares in Q1 2023, an estimated $391K.
Caxton Associates (New York) first reported a position in Viking Therapeutics in Q4 2020 and held it in 9 quarters.
Caxton Associates (New York)'s Viking Therapeutics position peaked at $849K in Q2 2022.
184 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2023.

Based on Caxton Associates (New York)'s 13F filing for Q1 2023, filed 15 May 2023.